Clinigen South Africa is part of Clinigen Group plc which is a rapidly-growing global specialty pharmaceutical and services company with a unique combination of businesses focused on delivering the right medicine to the right patient at the right time to improve the quality of people’s lives around the world. The Group consists of five synergistic businesses focused in three areas of global medicine supply: clinical trial, unlicensed and licensed medicines.
The complementary businesses operate efficiently in a complex global regulatory environment and can ensure that precious medicines are delivered securely and effectively, wherever they are needed throughout the product lifecycle. Clinigen Group provide patient access to their own and other pharmaceutical companies’ products, whether to meet unmet medical needs or for use in clinical trials.
A key strategy of the South African operations, whose pharmaceutical range consists of both propriety and in-licensed products, is a commitment to building lasting relationships with blue chip pharmaceutical and medical technology companies throughout the world. They support key customers and hospital pharmacists throughout the region as there is increasing demand for hospital based oncology, anti-infective, orphan and other crucial drugs in emerging markets. With their underlying philosophy of getting the right drug to the right patient in the quickest possible time, no matter the location.
The South African entity consists of four operational companies that provide a variety of products and services. The four companies are, Equity Pharmaceuticals, Novagen, Homemed and EMT.
Clinigen SA has five business units operating in South Africa:
Clinigen SA is part of the Clinigen Group that covers Africa and the Middle-East region.
Our Singapore office coordinates business in Asia while our partner company, LINK Healthcare Pte Ltd, handles our business in Australia and New Zealand.